The company remains in a pre-revenue stage with operating losses widening to $119.4 million in 2026Q1, driven by a surge in R&D expenditures from $35.6 million in 2023Q4 to $83.6 million.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - |
| Operating Expenses | 438.9M | 414.31M | 280.37M | 149.49M | 86.11M | 45.82M | 16.91M | 10.36M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 122.74M | 107.34M | 62.59M | 36.25M | 22.38M | 10.26M | 1.5M | 612K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - |
| Research & Development | 316.16M | 306.97M | 217.77M | 113.24M | 63.73M | 35.56M | 15.4M | 9.75M |
| R&D % of Revenue | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -438.9M | -414.31M | -280.37M | -149.49M | -86.11M | -45.82M | -16.91M | -10.36M |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -47.77% | -87.55% | -73.61% | -87.94% | -171.03% | -63.21% | - |
| EBITDA | -346.28M | 0 | 0 | -126.22M | -86.11M | -45.82M | -16.91M | 0 |
| EBITDA Margin % | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -7.34% | - | 100% | -46.58% | -87.94% | -171.03% | - | - |
| D&A (Non-Cash Add-back) | 102.23M | 414.31M | 280.37M | 0 | 0 | 0 | 0 | 10.36M |
| EBIT | -464.84M | -424.79M | -280.37M | -126.22M | -86.11M | -45.82M | -16.91M | -11.81M |
| Net Interest Income | 29.23M | 44.73M | 38.32M | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 42.09M | 44.73M | 38.32M | 23.27M | 0 | 0 | 0 | 0 |
| Interest Expense | 12.87M | 0 | 0 | 23.27M | 0 | 0 | 0 | 0 |
| Other Income/Expense | -10.58M | -10.48M | 20.38M | 23.27M | 4.25M | -521K | 2.35M | -1.45M |
| Pretax Income | -449.48M | -424.79M | -259.99M | -126.22M | -81.85M | -46.34M | -14.56M | -11.81M |
| Pretax Margin % | - | - | - | - | - | - | - | - |
| Income Tax | 596K | 585K | 764K | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.13% | -0.14% | -0.29% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -450.07M | -425.38M | -260.76M | -126.22M | -81.85M | -46.34M | -14.56M | -11.81M |
| Net Margin % | - | - | - | - | - | - | - | - |
| Net Income Growth % | -49.6% | -63.13% | -106.59% | -54.2% | -76.65% | -218.34% | -23.26% | - |
| Net Income (Continuing) | -450.07M | -425.38M | -260.76M | -126.22M | -81.85M | -46.34M | -14.56M | -11.81M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -5.72 | -5.85 | -3.93 | -2.17 | -1.65 | -2.13 | -0.64 | -0.24 |
| EPS Growth % | -38.04% | -48.85% | -81.11% | -31.52% | 22.54% | -232.81% | -166.67% | - |
| EPS (Basic) | - | -5.85 | -3.93 | -2.17 | -1.65 | -2.13 | -0.64 | -0.24 |
| Diluted Shares Outstanding | 78.67M | 72.69M | 66.41M | 58.22M | 49.67M | 21.78M | 22.86M | 48.28M |
| Basic Shares Outstanding | 78.67M | 72.69M | 66.41M | 58.22M | 49.67M | 21.78M | 22.86M | 48.28M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Clinical trial execution risk
As reported in recent financial statements, Nuvalent's quarterly R&D expenditures have surged to $83.6 million in 2026Q1, reflecting a consistent upward trajectory from the $35.6 million recorded in 2023Q4 as the company accelerates its pivotal clinical trial programs for NVL-520 and NVL-655.
The steady expansion in R&D spending suggests a deliberate strategy to compress development timelines, though it simultaneously intensifies the company's reliance on external capital. Investors should monitor whether this cost escalation yields proportional clinical milestones, as the current structure lacks any offsetting revenue to mitigate the impact on the bottom line.
Based on the company's reported figures, operating losses have widened significantly to $119.4 million in 2026Q1, demonstrating that the firm's administrative and research overhead continues to scale faster than any potential commercial progress, which remains non-existent at this stage of the corporate lifecycle.
The widening gap between SG&A and R&D costs indicates that the company is building out its operational infrastructure in anticipation of future commercialization. This trend suggests that the firm is currently in a high-burn phase where operating leverage is not yet a relevant metric for assessing performance.
According to historical income statement data, Nuvalent consistently utilizes stock-based compensation, which reached $22.1 million in 2025Q2, effectively masking the true cash-based operational deficit and complicating the assessment of the company's underlying financial health relative to its reported net loss of $109.3 million in 2026Q1.
The reliance on equity-based incentives appears to be a standard mechanism for talent retention in the biotechnology sector, yet it warrants further investigation regarding its dilutive impact on shareholders. Analysts should focus on cash burn metrics rather than net income to better understand the company's actual runway.
As evidenced by the shift in quarterly financial data, the period between 2024Q4 and 2026Q1 marks a critical inflection point where R&D spending accelerated sharply, signaling the transition from early-stage exploratory research to the resource-intensive execution of pivotal Phase 2 clinical trials for its lead assets.
This operational pivot suggests that the company has reached a stage where clinical data readouts will now dictate the firm's valuation more than ever before. The lasting impact of this transition is a permanently higher cost base that necessitates successful trial outcomes to justify the ongoing capital requirements.
Quick answers to the most common questions about buying NUVL stock.
For fiscal year 2025, Nuvalent, Inc. (NUVL) reported total revenue of $0.0M.
Nuvalent, Inc. (NUVL) reported a net loss of $425.4M for the fiscal year ending 2025.